Volume 1 · Issue 5
Neurodegeneration & the Aging Brain
From cognitive reserve to longitudinal biomarkers, this issue examines the progression of neurodegenerative conditions and the evidence used to distinguish aging from disease.
100 Creative Commons readings · Paulina Valenzuela, MD, Editor-in-Chief
Issue 5 · Reading list
Explore the research
100 readings · Page 3 of 5
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology.
Wouter van Rheenen, Rick A A van der Spek, Mark K Bakker, Joke J F A van Vugt et al.
Nature genetics · 2021
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
Epidemiology of amyotrophic lateral sclerosis: an update of recent literature.
Elisa Longinetti, Fang Fang
Current opinion in neurology · 2019
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia.
Jonathan D Rohrer, Ione O C Woollacott, Katrina M Dick, Emilie Brotherhood et al.
Neurology · 2016
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound.
Agessandro Abrahao, Ying Meng, Maheleth Llinas, Yuexi Huang et al.
Nature communications · 2019
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
The role of TDP-43 mislocalization in amyotrophic lateral sclerosis.
Terry R Suk, Maxime W C Rousseaux
Molecular neurodegeneration · 2020
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging.
B Ghetti, A L Oblak, B F Boeve, K A Johnson et al.
Neuropathology and applied neurobiology · 2015
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
An update on genetic frontotemporal dementia.
Caroline V Greaves, Jonathan D Rohrer
Journal of neurology · 2019
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
Cerebrospinal Fluid Inflammatory Cytokine Aberrations in Alzheimer's Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.
Xi Chen, Yang Hu, Zongze Cao, Qingshan Liu et al.
Frontiers in immunology · 2018
- Original article
ALS and frontotemporal degeneration · CC BY 3.0
Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion.
Adrian J Waite, Dirk Bäumer, Simon East, James Neal et al.
Neurobiology of aging · 2014
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
Projected increase in amyotrophic lateral sclerosis from 2015 to 2040.
Karissa C Arthur, Andrea Calvo, T Ryan Price, Joshua T Geiger et al.
Nature communications · 2016
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
C9orf72 Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
Ruxandra Dafinca, Jakub Scaber, Nida'a Ababneh, Tatjana Lalic et al.
Stem cells (Dayton, Ohio) · 2016
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications.
Jia Liu, Fei Wang
Frontiers in immunology · 2017
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis.
Vlad A. Korben, Alexander K Lyashchenko, Beatriz Blanco-Redondo, Paymaan Jafar-Nejad et al.
Nature medicine · 2022
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis.
Jik Nijssen, Laura H Comley, Eva Hedlund
Acta neuropathologica · 2017
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia.
Helois Radford, Julie A Moreno, Nicholas Verity, Mark Halliday et al.
Acta neuropathologica · 2015
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia.
Kelly L Williams, Simon Topp, Shu Yang, Bradley Smith et al.
Nature communications · 2016
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models.
M Catarina Silva, Fleur M Ferguson, Quan Cai, Katherine A Donovan et al.
eLife · 2019
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
Neurofilament light chain: a biomarker for genetic frontotemporal dementia.
Lieke H Meeter, Elise G Dopper, Lize C Jiskoot, Raquel Sanchez-Valle et al.
Annals of clinical and translational neurology · 2016
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study.
Ton Fang, Ahmad Al Khleifat, Jacques-Henri Meurgey, Ashley Jones et al.
The Lancet. Neurology · 2018
- Original article
ALS and frontotemporal degeneration · CC BY 4.0
Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
Federico Verde, Markus Otto, Vincenzo Silani
Frontiers in neuroscience · 2021
